Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials

BACKGROUND: The long acting β2-agonists, salmeterol and formoterol, have been recommended, by some, as first line treatment of stable chronic obstructive pulmonary disease (COPD). We reviewed evidence of efficacy and safety when compared with placebo or anticholinergic agents in patients with poorly...

Descripción completa

Detalles Bibliográficos
Autores principales: Husereau, Don, Shukla, Vijay, Boucher, Michel, Mensinkai, Shaila, Dales, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517721/
https://www.ncbi.nlm.nih.gov/pubmed/15339337
http://dx.doi.org/10.1186/1471-2466-4-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC517721/
https://www.ncbi.nlm.nih.gov/pubmed/15339337
http://dx.doi.org/10.1186/1471-2466-4-7

Ejemplares similares